Haisma HJ - Search Results

1

Cloning and characterization of human liver cytosolic beta-glycosidase.

de Graaf M, van Veen IC, van der Meulen-Muileman IH, Gerritsen WR, Pinedo HM, Haisma HJ. de Graaf M, et al. Among authors: haisma hj. Biochem J. 2001 Jun 15;356(Pt 3):907-10. doi: 10.1042/0264-6021:3560907. Biochem J. 2001. PMID: 11389701 Free PMC article.

2

Cytosolic beta-glycosidases for activation of glycoside prodrugs of daunorubicin.

de Graaf M, Pinedo HM, Quadir R, Haisma HJ, Boven E. de Graaf M, et al. Among authors: haisma hj. Biochem Pharmacol. 2003 Jun 1;65(11):1875-81. doi: 10.1016/s0006-2952(03)00183-7. Biochem Pharmacol. 2003. PMID: 12781339

3

Beta-glucuronidase-mediated drug release.

de Graaf M, Boven E, Scheeren HW, Haisma HJ, Pinedo HM. de Graaf M, et al. Among authors: haisma hj. Curr Pharm Des. 2002;8(15):1391-403. doi: 10.2174/1381612023394485. Curr Pharm Des. 2002. PMID: 12052215 Review.

4

Pronounced antitumor efficacy by extracellular activation of a doxorubicin-glucuronide prodrug after adenoviral vector-mediated expression of a human antibody-enzyme fusion protein.

de Graaf M, Pinedo HM, Oosterhoff D, van der Meulen-Muileman IH, Gerritsen WR, Haisma HJ, Boven E. de Graaf M, et al. Among authors: haisma hj. Hum Gene Ther. 2004 Mar;15(3):229-38. doi: 10.1089/104303404322886084. Hum Gene Ther. 2004. PMID: 15018732

5

A methylester of the glucuronide prodrug DOX-GA3 for improvement of tumor-selective chemotherapy.

de Graaf M, Nevalainen TJ, Scheeren HW, Pinedo HM, Haisma HJ, Boven E. de Graaf M, et al. Among authors: haisma hj. Biochem Pharmacol. 2004 Dec 1;68(11):2273-81. doi: 10.1016/j.bcp.2004.08.004. Biochem Pharmacol. 2004. PMID: 15498517

6

Characterization of novel anthracycline prodrugs activated by human beta-glucuronidase for use in antibody-directed enzyme prodrug therapy.

Houba PH, Leenders RG, Boven E, Scheeren JW, Pinedo HM, Haisma HJ. Houba PH, et al. Among authors: haisma hj. Biochem Pharmacol. 1996 Aug 9;52(3):455-63. doi: 10.1016/0006-2952(96)00248-1. Biochem Pharmacol. 1996. PMID: 8687500

7

Construction and characterization of a fusion protein of single-chain anti-carcinoma antibody 323/A3 and human beta-glucuronidase.

Haisma HJ, Brakenhoff RH, vd Meulen-Muileman I, Pinedo HM, Boven E. Haisma HJ, et al. Cancer Immunol Immunother. 1998 Jan;45(5):266-72. doi: 10.1007/s002620050442. Cancer Immunol Immunother. 1998. PMID: 9439650 Free PMC article.

8

Construction and characterization of a fusion protein of single-chain anti-CD20 antibody and human beta-glucuronidase for antibody-directed enzyme prodrug therapy.

Haisma HJ, Sernee MF, Hooijberg E, Brakenhoff RH, vd Meulen-Muileman IH, Pinedo HM, Boven E. Haisma HJ, et al. Blood. 1998 Jul 1;92(1):184-90. Blood. 1998. PMID: 9639515 Free article.

9

Distribution and pharmacokinetics of the prodrug daunorubicin-GA3 in nude mice bearing human ovarian cancer xenografts.

Houba PH, Boven E, van der Meulen-Muileman IH, Leenders RG, Scheeren JW, Pinedo HM, Haisma HJ. Houba PH, et al. Among authors: haisma hj. Biochem Pharmacol. 1999 Mar 15;57(6):673-80. doi: 10.1016/s0006-2952(98)00343-8. Biochem Pharmacol. 1999. PMID: 10037453

10

Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate.

Houba PH, Boven E, van der Meulen-Muileman IH, Leenders RG, Scheeren JW, Pinedo HM, Haisma HJ. Houba PH, et al. Among authors: haisma hj. Int J Cancer. 2001 Feb 15;91(4):550-4. doi: 10.1002/1097-0215(200002)9999:9999<::aid-ijc1075>3.0.co;2-l. Int J Cancer. 2001. PMID: 11251980

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

155 results

Search Page

Filters